Solvonis Therapeutics to host investor webinar on Oct 15

Solvonis Therapeutics plc will host an investor webinar on October 15, 2026, featuring its CEO and CSO. The webinar will discuss the company's strategy in addiction and mental health therapeutics, including its lead programs SVN-001 and SVN-002 for alcohol use disorder, and proprietary medicines SVN-015 for stimulant use disorder and SVN-114 for PTSD.